Contact this trialFirst, we need to learn more about you.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Graft-versus-Host Disease
Recruiting1 awardPhase 2
Atlanta, Georgia
This trial is testing a new treatment for GVHD made up of Ibrutinib and Rituximab. 35 patients will be enrolled and monitored for 12 months to see how effective and safe the treatment is.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.